Glaxosmithkline Share News (GSK)

GSK spins off Haleon in biggest European listing for decade

LONDON, July 18 (Reuters) - British drugmaker GSK spun off its consumer health business on Monday in the biggest listing in Europe for more than a decade.

GSK consumer arm Haleon set to begin trading in London on Monday

(Alliance News) - Haleon PLC, the consumer healthcare product arm of GSK PLC, will start trading on Monday, becoming effectively by far the biggest new listing in London in 2022, a poor year so far for initial public offerings.

LONDON BROKER RATINGS: JPMorgan downgrades Admiral and Direct Line

(Alliance News) - The following London-listed shares received analyst recommendations Friday morning and Thursday:

After bruising year, GSK approaches consumer split in better health

LONDON, July 15 (Reuters) - Things are looking up for GSK and its chief Emma Walmsley as the British drugs giant prepares to spin off its consumer health business on Monday in London’s biggest listing in a decade and the company's most radical shake-up in 20 years.

EU drugs regulator open to COVID boosters that target older Omicron offshoots

LONDON, July 7 (Reuters) - The European Medicines Agency (EMA) is open to using next generation COVID-19 vaccines that target older offshoots of the Omicron variant this fall, an official said on Thursday, amid a rise in cases due to new Omicron subvariants.

IN BRIEF: GSK shareholders vote in favour of Haleon demerger

GSK PLC - London-based pharmaceutical company - At general meeting, shareholders vote near unanimously in favour of proposed demerger of Haleon PLC from GSK, with the former's shares expected to list on the London Main Market at the open on July 18.

CureVac files patent lawsuit in Germany against BioNTech over mRNA technology

BERLIN, July 5 (Reuters) - CureVac has filed a patent lawsuit in Germany against BioNTech over its use of mRNA technology, marking one of the first known cases of a company going to court amid the fierce competition to develop a vaccine against the coronavirus.

IN BRIEF: Sareum notes updated payment terms after GSK buy of SRA737

Sareum Holdings PLC - Cambridge, England-based drug developer for cancer and autoimmune diseases - Notes that GSK PLC has completed its acquisition of Sierra Oncology Inc, the licence holder of SRA737, for USD1.9 billion. SRA737 was discovered and initially developed by scientists at the Institute of Cancer Research in collaboration with Sareum.

IN BRIEF: GSK completes acquisition of Sierra Oncology

GSK PLC - London-based pharmaceutical company - Completes acquisition of Sierra Oncology Inc, for USD55 per share in cash, representing a total value of USD1.9 billion. Notes acquisition includes momelotinib, a late-stage potential treatment for myelofibrosis patients with anaemia. Last month, Sierra presented data for the treatment from phase III Momentum trial, which met all its key primary and secondary endpoints. The drug showed a statistically meaningful benefit on symptoms, splenic response, and anaemia.

Covid-19 cases surge during latest week due to BA.4 and BA.5 Covid-19 sub-variants

(Sharecast News) - The number of new coronavirus cases in Britain jumped again during the preceding week, likely due to the more infectious BA.4 and BA.5 variants of the Omicron variant of Covid-19.

UK shareholder meetings calendar - next 7 days

GSK seeks expanded approval for shingles vaccine in Japan

(Alliance News) - GSK PLC on Tuesday announced it has submitted a regulatory application for Shingrix, a shingles vaccine, to the Japanese Ministry Health, Labour & Welfare.

GSK submits shingles vaccine application in Japan for over 18s

(Sharecast News) - Pharma giant GlaxoSmithKline on Tuesday said it had submitted a regulatory application Japan's Ministry of Health, Labour and Welfare (MHLW) for its Shingrix shingles vaccine for adults aged 18 years and older who are at increased risk.

GSK posts positive interim results from hepatitis treatment trial

(Alliance News) - GSK PLC on Saturday announced positive interim results from its B-Clear phase IIb trial, which tested bepirovirsen as a treatment of chronic hepatitis B.

European shares mark strong end to nervous week

June 24 (Reuters) - European stocks jumped 2.6% on Friday, pushing them into positive territory for the week as investors started to scale back central bank tightening bets, spurring inflows into risky assets.